Phase I evaluation of SOAz (1,3,3,5,5Pentakis(aziridino)-1λ6,2,4,6,3λ5,5λ5thiatriaza-diphosphorine-1-oxide) in a weekly schedule
- 1 May 1984
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 20 (5), 645-649
- https://doi.org/10.1016/0277-5379(84)90011-7
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Phase i clinical trial of (NPAz2)2NSOAz: ‘SOAz’Cancer Chemotherapy and Pharmacology, 1983
- Clinical pharmacokinetics of (NPAz2)2NSOAz: ‘SOAz’Cancer Chemotherapy and Pharmacology, 1983
- Determination of the antitumor agent SOAz (1,3,3,5,5 Pentakis(Aciridino)-1λ6,2,4,6,3λ5,5λ5 Thia-Triazadiphosphorine-1-Oxide) by a gas chromatographic assay suitable for pharmacokinetic studies in manCancer Chemotherapy and Pharmacology, 1983
- Cytostatic Activity of Inorganic Heterocycles in an in vitro Screening SystemOncology, 1983
- PHASE-I STUDY OF SOAZ1982
- New designs in inorganic ring systems as anticancer drugs. Antitumor activity of the aziridino (ethyleneimino) derivatives (NPAz2)2NSOX with X = F, Az, PhCancer Letters, 1981
- Antitumour activity of some cyclophosphazenesEuropean Journal of Cancer (1965), 1979